Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist.
PURPOSE To evaluate the incidence of  Intraoperative Floppy Iris syndrome ( IFIS )  in relation to the usage of alpha(1)-adrenoceptor antagonists . DESIGN Prospect i ve , interventional case series . METHODS In 2,643 consecutive eyes of 1,968 patients undergoing cataract surgery , occurrence of IFIS and use of alpha(1 ) antagonists were recorded . RESULTS IFIS was observed in 29 eyes ( 1.1 % ) of 25 male patients , all of whom were receiving  alpha(1 ) antagonists . In those receiving systemic tamsulosin , alpha(1A ) selective antagonist ,  IFIS developed in 25 ( 43.1 % ) of 58 eyes . In those receiving systemic naftopidil , alpha(1A ) and alpha(1D ) antagonists , IFIS was found in 4 ( 19.0 % ) of 21 eyes . There was no case of IFIS in patients who received other systemic alpha(1 ) antagonists and in eyes treated with bunazosin eyedrops , a nonselective alpha(1 ) antagonist . CONCLUSIONS IFIS occurred in 1.1 % of cases treated with systemic alpha(1A)-adrenoceptor antagonists for benign prostatic hypertrophy . Topical nonselective alpha(1 ) antagonist did not induce IFIS
Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .